Deeper understanding of the role of excipients in drug formulations is leading manufacturers and pharmacopoeias to develop new more science-based approaches and standards for them. Variability of excipients should be expected: the key is to know which variables are important - and how to counterbalance them. The flexibility of QbD could play a key role. Compendial tests often do not focus on the critical attributes. USP and EP are working to upgrade their excipient standards. USP <1059> draft is seen as step in the right direction with its offering of functional guidance in a general information chapter. Industry fears the 'non-mandatory' functionality-related tests the EP wants to add to excipient monographs would eventually become mandatory. FDA and IPEC work to unfetter novel excipients. FDA would create an excipient functionality database. Regulatory requirements for excipients could be helpful, but progress is slow. Third-party certification could suffice in the interim, though uptake remains slow.
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.
Exclusive analysis by the Pink Sheet explores how non-submissions by pharmaceutical companies to England’s health technology appraisal body are impacting the availability of medicines on the National Health Service.
As South Korea's new president immediately gets to work on setting initial policies, essential drug supplies, R&D incentives and AI-driven digital healthcare are among the key topics in focus.
